Dr Reddy’s Laboratories Ltd has won a favourable judgement in a patent infringement litigation in the US.
The United States District Court, Delaware, has delivered judgement in favour of Dr Reddy’s Laboratories, ruling that the proposed generic version of Suboxone (buprenorphine and naloxone) sublingual film does not infringe US patent as asserted by Indivior.
A company spokesperson stated: "The judgement reiterates our commitment to providing affordable and innovative medicines that address the unmet and under-met needs of patients around the world.”
Suboxone (buprenorphine and naloxone) sublingual film is indicated for the maintenance treatment of opioid dependence.
Reckitt Benckiser developed Suboxone sublingual film using MonoSol Rx’s PharmFilm technology. In December 2014, Reckitt Benckiser de-merged its pharmaceuticals business as Indivior.
The US Food and Drug Administration (USFDA) has approved Suboxone film in four different strengths.
The Hyderabad-based company’s scrip zoomed 9.48 per cent over the previous close and is trading at Rs 2,212 on the Bombay Stock Exchange on Friday.